Category: CovidienSyndicate content

MassDevice.com +3 | The top 3 med-tech stories for May 10, 2012.

May 10, 2012 by MassDevice staff

Riata's survival rates called "significantly worse" in an independent study, DePuy may be showing its hand in defending its recalled metal-on-metal hips ahead of court hearings and Covidien denies a widely disseminated rumor that it cut 200 workers to offset the cost of the medical device tax.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien denies layoffs tied to device tax

May 10, 2012 by Arezu Sarvestani

Contrary to a widely circulated statement, Covidien's decision to cut workers and shift production overseas was not motivated by the impending medical device tax, the company says.

Covidien logo

Although Covidien (NYSE:COV) chairman, president & CEO Jose Almeida considers the impending 2.3% medical device tax "absurd," he's far from implementing dramatic gestures to cope with the new burden.

The company confirmed with MassDevice.com that reports of layoffs and overseas shifts ahead of the levy were inaccurate, despite being widely disseminated.

MassDevice.com +3 | The top 3 med-tech stories for May 8, 2012.

May 8, 2012 by MassDevice staff

A GPO asks the IRS to ban device makers from baking the cost of the med-tech tax in product price hikes, a House panel speeds the FDA user fee bill to the next stage and Covidien jumps into the renal denervation market with CE Mark in hand.

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.

If you read nothing else today, make sure you're still in the know with MassDevice +3.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien jumps into the high blood pressure arena with CE Mark in hand through $230M Maya merger

May 8, 2012 by MassDevice staff

Covidien vaults into the renal denervation devices market with the acquisition of Maya Medical in a deal worth up to $230 million, gaining the OneShot system which already holds CE Mark approval and is set to begin a post-CE Mark clinical trial.

OneShot by Covidien

Covidien (NYSE:COV) launched into the renal denervation market with a surprise introduction of its OneShot system, which already has CE Mark approval in the European Union.

The OneShot system was acquired through the acquisition of Maya Medical late last month in a deal worth up to $230 million.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Masimo misses Q1 forecast on discounted Covidien royalties

May 3, 2012 by MassDevice staff

Masimo's 1st quarter earnings take a hit, missing Wall Street's expectations, as fewer royalty dollars come in from Covidien.

Masimo logo

Masimo's (NSDQ:MASI) 1st quarter earnings, issued yesterday, missed the mark by just a hair as the company's increased sales couldn't outpace lost royalty revenues.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien, GE Healthcare ink 5-year deal

May 3, 2012 by MassDevice staff

Medical device giants Covidien and GE Healthcare ink a pact to integrate Covidien technologies into GE Healthcare's patient monitors.

MassDevice.com news
MassDevice.com news

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

More deals ahead for Covidien? | Wall Street Beat

May 2, 2012 by MassDevice staff

Analysts speculate that more buyouts may be in Covidien's near future; Regulatory and economic uncertainties drive a slowdown in hospital capital spending; Medic Vision and BRIT Systems sign U.S. deal for SafeCT; ConvaTec buys AbViser Medical for an undisclosed amount; Corpak acquires Micronix's assets; Synexus nabs Osteomed, terms not disclosed; HCL Technologies and Becton Dickinson join R&D forces; EndoEvolution licenses its MIS suturing device to Edwards Lifesciences'; Teleflex hits a new 52-week high; plus, a Funding Roundup and analysts' ups and downs.

MassDevice.com Wall Street Beat

As Covidien (NYSE:COV) closed its 4th recent acquisition, analysts speculated that there may be more deals on the near future.

The Mansfield, Mass.-based company may be looking to pick up some assets in hypertension treatment, or may keep its sights on additional acquisitions in Israel.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp